Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Malignant Melanoma

  Free Subscription


06.11.2017

1 Am J Dermatopathol
3 Ann Surg Oncol
1 Anticancer Res
1 Biochem Biophys Res Commun
1 Br J Dermatol
5 Cancer Res
2 Eur J Dermatol
1 Int J Cancer
2 J Am Acad Dermatol
1 J Biol Chem
1 J Invest Dermatol
6 Melanoma Res
2 PLoS One
1 Proc Natl Acad Sci U S A


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Dermatopathol

  1. GARRIDO MC, Maronas-Jimenez L, Morales-Raya C, Ruano Y, et al
    Acquisition of Somatic NRAS Mutations in Central Nervous System Melanocytes: A Predisposing Risk Factor to Primary Melanoma of the Central Nervous System, a Frequently Forgotten Pitfall in Congenital Nevi.
    Am J Dermatopathol. 2017 Oct 17. doi: 10.1097/DAD.0000000000001039.
    PubMed     Text format     Abstract available


    Ann Surg Oncol

  2. CRAWFORD AB, Nessim C, Weaver J, van Walraven C, et al
    Wait Times for Melanoma Surgery: Is There an Association with Overall Survival?
    Ann Surg Oncol. 2017 Nov 3. doi: 10.1245/s10434-017-6146.
    PubMed     Text format     Abstract available

  3. HOLTKAMP LHJ, Wang S, Wilmott JS, Madore J, et al
    Reply to comment on: Detailed Pathological Examination of Completion Node Dissection Specimens and Outcome in Melanoma Patients with Minimal (< 0.1 mm) Sentinel Lymph Node Metastases.
    Ann Surg Oncol. 2017 Oct 27. doi: 10.1245/s10434-017-6170.
    PubMed     Text format    

  4. ROSSI CR, Mocellin S, Campana LG, Borgognoni L, et al
    Prediction of Non-sentinel Node Status in Patients with Melanoma and Positive Sentinel Node Biopsy: An Italian Melanoma Intergroup (IMI) Study.
    Ann Surg Oncol. 2017 Oct 24. doi: 10.1245/s10434-017-6143.
    PubMed     Text format     Abstract available


    Anticancer Res

  5. SUCKOW MA, Wolter WR, Duffield GE
    The Impact of Environmental Light Intensity on Experimental Tumor Growth.
    Anticancer Res. 2017;37:4967-4971.
    PubMed     Text format     Abstract available


    Biochem Biophys Res Commun

  6. LUAN W, Zhou Z, Zhu Y, Xia Y, et al
    miR-137 inhibits glutamine catabolism and growth of malignant melanoma by targeting glutaminase.
    Biochem Biophys Res Commun. 2017 Oct 30. pii: S0006-291X(17)32137.
    PubMed     Text format     Abstract available


    Br J Dermatol

  7. TRAN AD, Fogarty G, Nowak AK, Espinoza D, et al
    A systematic review and meta-analysis of utility estimates in melanoma.
    Br J Dermatol. 2017 Oct 27. doi: 10.1111/bjd.16098.
    PubMed     Text format     Abstract available


    Cancer Res

  8. DONIA M, Harbst K, van Buuren M, Kvistborg P, et al
    Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNgamma Signaling.
    Cancer Res. 2017;77:4562-4566.
    PubMed     Text format     Abstract available

  9. PICCO N, Sahai E, Maini PK, Anderson ARA, et al
    Integrating Models to Quantify Environment-Mediated Drug Resistance.
    Cancer Res. 2017;77:5409-5418.
    PubMed     Text format     Abstract available

  10. LI P, Wuthrick E, Rappaport JA, Kraft C, et al
    GUCY2C Signaling Opposes the Acute Radiation-Induced GI Syndrome.
    Cancer Res. 2017;77:5095-5106.
    PubMed     Text format     Abstract available

  11. BLATTNER C, Fleming V, Weber R, Himmelhan BS, et al
    CCR5+ myeloid-derived suppressor cells are enriched and activated in melanoma lesions.
    Cancer Res. 2017 Oct 31. pii: canres.0348.2017.
    PubMed     Text format     Abstract available

  12. HUA KT, Hong JB, Sheen YS, Huang HY, et al
    MicroRNA-519d promotes melanoma progression by downregulating EphA4.
    Cancer Res. 2017 Nov 1. pii: canres.1933.2017.
    PubMed     Text format     Abstract available


    Eur J Dermatol

  13. KOMORI T, Otsuka A, Kusuba N, Taniguchi K, et al
    Rapid regression of metastatic brain tumours in a melanoma patient after dabrafenib/trametinib therapy.
    Eur J Dermatol. 2017;27:548-549.
    PubMed     Text format    

  14. RUSSO I, Zorzetto L, Frigo AC, Chiarion Sileni V, et al
    A comparative study of the cutaneous side effects between BRAF monotherapy and BRAF/MEK inhibitor combination therapy in patients with advanced melanoma: a single-centre experience.
    Eur J Dermatol. 2017;27:482-486.
    PubMed     Text format     Abstract available


    Int J Cancer

  15. WU Y, Shi H, Jiang M, Qiu M, et al
    The clinical value of combination of immune checkpoint inhibitors in cancer patients: A meta-analysis of efficacy and safety.
    Int J Cancer. 2017;141:2562-2570.
    PubMed     Text format     Abstract available


    J Am Acad Dermatol

  16. OHN J, Mun JH
    Reply to: "Limitations and challenges of nail unit dermoscopy in longitudinal melanonychia".
    J Am Acad Dermatol. 2017;76:e73-e74.
    PubMed     Text format    

  17. KNACKSTEDT T, Jellinek NJ
    Limitations and challenges of nail unit dermoscopy in longitudinal melanonychia.
    J Am Acad Dermatol. 2017;76:e71-e72.
    PubMed     Text format    


    J Biol Chem

  18. PLITZKO B, Kaweesa EN, Loesgen S
    The Natural Product Mensacarcin Induces Mitochondrial Toxicity and Apoptosis in Melanoma Cells.
    J Biol Chem. 2017 Oct 26. pii: jbc.M116.774836. doi: 10.1074/jbc.M116.774836.
    PubMed     Text format     Abstract available


    J Invest Dermatol

  19. ELIADES P, Tsao H
    New Insights into the Molecular Distinction of Dysplastic Nevi and Common Melanocytic Nevi-Highlighting the Keratinocyte-Melanocyte Relationship.
    J Invest Dermatol. 2016;136:1933-5.
    PubMed     Text format     Abstract available


    Melanoma Res

  20. TANG Y, Xie C, Zhang Y, Qin Y, et al
    Overexpression of mRNA-decapping enzyme 1a predicts disease-specific survival in malignant melanoma.
    Melanoma Res. 2017 Oct 25. doi: 10.1097/CMR.0000000000000406.
    PubMed     Text format     Abstract available

  21. PACHMANN K, Willecke-Hochmuth R, Schneider K, Kaatz M, et al
    Circulating epithelial tumor cells as a prognostic tool for malignant melanoma.
    Melanoma Res. 2017 Oct 25. doi: 10.1097/CMR.0000000000000407.
    PubMed     Text format     Abstract available

  22. ROBINSON JP, Rebecca VW, Kircher DA, Silvis MR, et al
    Resistance mechanisms to genetic suppression of mutant NRAS in melanoma.
    Melanoma Res. 2017;27:545-557.
    PubMed     Text format     Abstract available

  23. HALLMEYER S, Gonzalez R, Lawson DH, Cranmer LD, et al
    Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E.
    Melanoma Res. 2017;27:585-590.
    PubMed     Text format     Abstract available

  24. SCHINZARI G, Rossi E, Cassano A, Dadduzio V, et al
    Cisplatin, dacarbazine and vinblastine as first line chemotherapy for liver metastatic uveal melanoma in the era of immunotherapy: a single institution phase II study.
    Melanoma Res. 2017;27:591-595.
    PubMed     Text format     Abstract available

  25. MENZIES S, Barry R, Ormond P
    Multiple primary melanoma: a single centre retrospective review.
    Melanoma Res. 2017;27:638-640.
    PubMed     Text format     Abstract available


    PLoS One

  26. ZHENG X, Tang H, Zhao X, Sun Y, et al
    Long non-coding RNA FTH1P3 facilitates uveal melanoma cell growth and invasion through miR-224-5p.
    PLoS One. 2017;12:e0184746.
    PubMed     Text format     Abstract available

  27. TIWARY S, Xu L
    Correction: FRIZZLED7 Is Required for Tumor Inititation and Metastatic Growth of Melanoma Cells.
    PLoS One. 2017;12:e0187388.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  28. MGRDITCHIAN T, Arakelian T, Paggetti J, Noman MZ, et al
    Targeting autophagy inhibits melanoma growth by enhancing NK cells infiltration in a CCL5-dependent manner.
    Proc Natl Acad Sci U S A. 2017;114:E9271-E9279.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: